In most medical device companies, missing a sales quota is rarely a minor event. Unlike high-velocity industries where short-term fluctuations can be absorbed, MedTech operates within tighter constraints, with finite markets and lengthy sales cycles. Decisions require alignment across multiple stakeholders, and each opportunity carries meaningful revenue weight.
When a quarterly revenue goal misses the mark, it’s often a structural signal – something in the system has broken down. Either pipeline assumptions were off, or deals didn’t progress as expected. Maybe stakeholders weren’t aligned and timelines extended beyond forecast.
Whatever the cause, the next step that MedTech organizations take can either set them up for revenue recovery or send them into a downward spiral.
Thinking About Cutting Back on Marketing? Think Again.
After falling short of a revenue goal, the instinctive response for many MedTech organizations is to pull back on near-term expenses, most frequently marketing. The hope is that cutting back can help hit profitability targets. The reality is that this approach sacrifices future revenue for short-term gain.
More so than perhaps any other industry, medical device marketing is built to facilitate long-term financial success. The industry’s lengthy validation and sales cycles mean that it can take years for sales opportunities to present themselves. Naturally, reducing marketing efforts today causes costly downstream troubles.
Diminished brand recognition, increased competition, dwindled influence along the finite amount of decision-makers relevant to your solution—without consistent marketing, these challenges become a reality that threatens pipelines at every level.
If today’s revenue shortfalls must truly be offset, consider scaling back on other non-commercial expenses. Doing so can keep a consistent, healthy pipeline intact for future revenue capture.
Building a Stronger Pipeline
A missed quota isn’t the problem, it’s the outcome. The real issue exists upstream in how opportunities were identified, developed, advanced and supported. By addressing common pipeline issues, medical device companies can build a reliable framework to recover revenue and prevent future shortfalls.
Step 1: Rebuild Pipeline Accuracy
The first step in revenue recovery is not acceleration. It’s clarity. Before organizations can improve performance, it’s important to understand what’s actually closable. Pipeline truth is not simply more accurate reporting, it’s alignment between what’s shown in the system and what is happening in the field.
In an accurate pipeline, deal stages reflect real progress. Stakeholder engagement is verified. Next steps are defined and scheduled. Clinical and economic validation are actively being developed. And there is absolute alignment between marketing and sales teams.
In a misleading pipeline, deals may be entered late (or never) and are often advanced based on optimism. As a result, marketing teams lack sufficient insight into lead quality, making it impossible to optimize lead gen strategy.
Step 2: Focus Marketing & Sales Efforts on Opportunities that are Most Likely to Close
Once pipeline accuracy is established, the next step is not rebuilding everything – it’s focusing. In medical device markets, not all opportunities are equal. Some are structurally incapable of closing in the near term. Others are delayed by institutional constraints that can’t be accelerated. And some, while close to the finish line, require targeted intervention to move forward.
Consistently hitting revenue goals depends on identifying that third group. MedTech organizations – especially those with limited marketing and sales resources – should shift from broad pipeline management to selective opportunity acceleration, and use those same insights to drive more efficient demand generation and demand capture strategies at the top of the funnel.
This means prioritizing deals where:
- Clinical alignment is largely in place
- Economic stakeholders are engaged
- A defined path to decision exists
In turn, those same parameters can be used to develop marketing campaigns that produce higher-quality leads that are more likely to close. These are the opportunities that can materially impact near-term revenue. The role of medical device leadership in this phase is not to increase pressure, but to remove friction. Deals rarely stall because of a lack of interest. They stall because of uncertainty, misalignment or unaddressed risk.
Clinical stakeholders often require deeper clinical validation to support their recommendations, while economic buyers look for clearer financial justification before moving forward. At the same time, procurement processes can stall when documentation is incomplete or next steps are not clearly defined. Accelerating sales opportunities comes from identifying and addressing those specific barriers.
This is where marketing plays a critical role: Equipping sales teams with targeted enablement assets to advance complex opportunities, reinforcing both clinical and economic value through strategic campaigns and content and enabling internal advocacy within target institutions by educating key decision-makers. (Interested in taking this step? Learn how Jairus helps MedTech companies accelerate sales opportunities.)
Step 3: Rebuild a System That Prevents Future Shortfalls
Even after revenue rebounds, it’s important to evaluate and correct the underlying challenges that led to the initial shortfall. Without this step, organizations enter a predictable cycle. A quarter’s sales goal is missed. Activity increases. Performance temporarily improves. Structural issues remain. And the pattern repeats.
Avoiding that cycle begins with evaluating how your pipeline is developed. High-performing MedTech organizations do not rely on volume-based demand generation. They focus on a defined prospecting strategy that identifies which opportunities truly matter, which stakeholders influence decisions and what progression actually looks like within those environments.
As part of that process, marketing should be embedded in the sales process, not upstream from it. When executed effectively, this phase produces immediate impact. Close rates improve, sales cycles shorten and revenue begins to stabilize.
How does that happen? Through absolute alignment between marketing and sales, with shared definitions of success, clear prospect prioritization and full visibility across the funnel. It also requires a strong thought leadership strategy where content is designed not just for awareness, but to actively support decision-making. Case studies, clinical data, economic models and workflow analyses become tools that help stakeholders justify adoption internally. (Missing those assets? Find out how to create them fast).
At the same time, sales teams provide real-time insight into objections, delays and competitive dynamics, allowing marketing to continuously refine messaging and campaigns. Over time, this approach creates predictability and scalability. Opportunities move forward more consistently, and performance becomes less dependent on short-term spikes in activity.
Ask the Right Questions to get Revenue Back on Track
If a missed sales quota reveals a weakness, it also creates an opportunity – not just to recover, but to redesign. Because in medical device markets, growth is not driven by how much you do. It’s driven by how well your marketing and sales systems work.
High-performing MedTech organizations understand that revenue is not simply an output of activity, but of system design. As a result, they ask fundamentally different questions:
Not “How do we generate more leads?” but “Which accounts can realistically close, and what’s required to move them forward?”
Not “How do we increase marketing performance?” but “How do marketing and sales operate as a unified system to drive opportunities forward?”
Not “How do we recover this quarter?” but “How do we ensure this doesn’t happen again?”
That shift reframes decision-making. It prioritizes clarity over optimism, focus over volume and alignment over activity. If your medical device, life science, digital health, revenue cycle or biotech company is struggling to meet sales goals, schedule a discovery call to learn how Jairus can help.
